



UCLA UROL

UPDATE



Top: Attendees of the Clinical Society of Genitourinary Surgeons annual meeting held at UCLA last November, visiting the Skirball Cultural Center. Bottom: Event honoring the UCLA Gender Health Program with the Cultural North Star Team Award from the David Geffen School of Medicine at UCLA. Right: Dr. Robert Reiter, principal investigator of the UCLA Prostate Cancer SPORE, speaking at the 14th Annual Multi-Institutional Prostate Cancer Program meeting held at UCLA last year.

Department's Educational Mission Reaches Wide-Ranging Audiences

he audiences vary considerably — from some of the nation's most noted academic urologists and most prominent prostate cancer research groups to urologists in private practice spanning rural communities and urban centers across the country, as well as health care providers outside of urology seeking to improve their interactions and treatments of marginalized and underserved populations. But regardless of the setting, the topic, or the attendees, UCLA Urology

continues to be proactive in its efforts to advance research and clinical care in ways that will improve outcomes for patients at UCLA and well beyond.

Last November, UCLA Urology hosted the annual meeting of the Clinical Society of Genitourinary Surgeons (CSGUS), a gathering of the nation's leading academic urologists. The CSGUS consists of just 25 active members, nearly all of them chairs of urology departments at major universities.

Approximately 15 others serve as emeritus members, rounding out a rarefied society that has met annually for more than a century.

"The CSGUS meeting represents a brain trust of academic urology convening in one place over a weekend, and it's quite a humbling experience to look around and see these giants of the field all in one room," says Dr. Mark S. Litwin, UCLA Urology professor and chair, who led the meeting's organizing team.

continued on page 2

Spring 2023VOL. 34 | NO. 2

	VOL. 54 NO. 2
New Faces	р3
Alumni Profile	p4
Healthy at Every Age	p4
Letter from the Chair	r p5
Kudos	p6
Donor Spotlight	p7
In Memoriam	p7
The Men's Clinic at U	JCLA p8

Educating Wide- Ranging Audiences

For information on making a gift to UCLA Urology, please log on to http://giving.ucla.edu/urology or call (310) 206-4565.

continued from cover



Top: Poster presentation at the 14th Annual Multi-Institutional Prostate Cancer Program held at UCLA last year. Bottom: General session of the annual UCLA State-of-the-Art Urology Conference.

For the meeting, UCLA Urology organized a day of academic presentations, followed by a day filled with non-medical talks covering compelling topics in the social sciences and humanities, with social engagements rounding out the weekend. For the academic day, a wide array of UCLA Urology faculty members delivered brief presentations on their research, each followed by a thought-provoking questionand-answer session.

In addition to allowing faculty to showcase their work, which can lead to additional scientific interest and collaborations, the presentations and exchanges between UCLA Urology scholars and the highly accomplished CSGUS members provided unique

"I've seen coffee-break

conversations that

turned into highly

productive and fruitful

collaborations."

educational opportunities for trainees. "In urology, we like to work together and help each other rather than be in competition," Dr. Litwin says. "I've seen coffee-break conversations that turned into highly productive and fruitful collaborations."

Just as the CSGUS meeting convened top genitourinary surgeons, the 14th Annual Multi-Institutional Prostate Cancer Program brought

together leaders in the field of translational prostate cancer research for a meeting held at UCLA's Meyer and Renee Luskin Conference Center from February 27 to March 1, 2022. The meeting included more than 200 prostate cancer researchers from more than a dozen institutions —

representing current and former Specialized Programs of Research Excellence (SPOREs), the highest designation for prostate cancer research from the National Cancer Institute (NCI).

Since 2004, the UCLA Prostate Cancer Program has received continuous funding from the NCI as a SPORE. Under the leadership of **Dr. Robert Reiter**, UCLA Urology professor, the UCLA SPORE — one of only seven currently funded — is a multidisciplinary and translational research program that draws scientists and clinicians

from diverse fields together to develop new and innovative approaches to improving the diagnosis, prognosis, and treatment of prostate cancer.

In the nearly 20 years since the UCLA program earned its SPORE designation, the field of prostate cancer research has grown at a rapid clip, with UCLA playing a central role in advances ranging from the development of new therapeutics to the introduction of novel imaging techniques and biomarkers to improve the way the disease is diagnosed and managed. With that leadership role comes the responsibility to organize and host meetings of the SPORE members, Dr. Reiter notes. The SPOREs are highly collaborative, sharing resources, ideas, and updates on research progress. Inter-SPORE meetings began on the East Coast before moving to the West Coast for the first time last year, with UCLA hosting the event and co-organizing it alongside the University of Washington-based Pacific Northwest Prostate Cancer SPORE.

"It was a packed meeting, with both senior and young investigators exchanging information on the gamut of issues in translational and clinical prostate cancer," Dr. Reiter says. "Because of COVID-19, it was the first time we had all been together in a while, and there was a great deal of excitement and interaction. You see old friends, meet new investigators, learn what others are doing, and in some cases forge new collaborations." The group's next meeting will also take place at UCLA, in March of 2024.

Given the challenges of keeping up with the latest advances in urology while also maintaining a busy private practice, urologists and other practitioners across the country stand to benefit greatly from

practical, evidence-based information on the most challenging management problems they face. The UCLA State-of-the-Art Urology Conference, which held its 48th annual meeting March 3-5, 2023, at the Luskin Conference Center, has earned a reputation as one of the premier continuing

education courses of its kind. "Our goal each year is to provide practical and updated information to urologists in private practice that they can immediately bring back to their communities and use to help their patients," says **Dr. William J. Aronson**, the UCLA Urology professor who chairs the course.

Among the longest-running specialty programs, State-of-the-Art draws more than 200 urology providers (including urologists, physician assistants, and nurse practitioners) from all over the country for a two-and-a-half-day course that provides continuing medical education credits as well as fluoroscopy certification credits. Experts from the UCLA Urology faculty, as well as visiting speakers from outside UCLA, present information and techniques covering a wide array of topics — the 2023 conference included sessions on female pelvic medicine, male voiding dysfunction, urolithiasis/endourology, men's health, prostate cancer, bladder cancer, kidney cancer, optimizing cancer care, urethral stricture disease, genderaffirming surgery, urologic dermatology, and pediatric urology.

One of the keys to the conference's success is the care taken by the program's organizers — in addition to Dr. Aronson, co-chairs include **Dr. Karim Chamie**, UCLA Urology associate professor; and **Dr. Craig Canfield**, a community-based urologist in San Luis Obispo, California, and former UCLA Urology trainee — to ensure that the program best meets the needs of its audience. Planning for each annual conference begins almost immediately after the previous year's is completed. Dr. Aronson's group reviews each presentation well in advance to ensure that it is both concise and practical. At the conference, ample time is allotted to discussions, ensuring that all questions are addressed.

For the UCLA Gender Health Program (GHP), a multidisciplinary UCLA Health program co-directed by Dr. Litwin, the highest priority is providing comprehensive medical and surgical care to its transgender and gender-diverse patients. But, recognizing the need to improve access to quality health services for a historically marginalized and underserved population, the program has also initiated a variety of educational programs for providers and trainees throughout UCLA and across the country.

"It was clear from the start that, while first and foremost we want


to ensure that the patients in our program receive competent, compassionate care, being part of UCLA Health gives us the opportunity to do much more than that," explains **Chris Mann**, a clinical social worker who was GHP's founding program manager.

With that in mind, GHP actively seeks to educate providers and the public, both at UCLA and nationally. The program's leaders have conducted trainings across the UCLA Health enterprise, for everyone from providers to call-center personnel, on how to appropriately engage with and support transgender and gender-diverse patients. As part of the David Geffen School of Medicine at UCLA (DGSOM) curriculum, GHP has trained first-year medical students on providing intake assessments for new Gender Health Program patients across the age spectrum. For those outside UCLA, the program holds a biannual gender health conference to educate attendees on issues such as developing an informed gender-affirming care program, basic and advanced hormone therapy and gender-affirming surgery, and behavioral health care for transgender and gender-diverse patients.

In January, GHP's care coordination team received the Cultural North Star Team Award from DGSOM in recognition of the teamwork that serves as the cornerstone of the medical school's collaborative environment, as well as the mission of the Cultural North Star Initiative: Do What's Right. Make Things Better. Be Kind. "There are many providers who see the importance of delivering quality, compassionate care for transgender and gender-diverse people, but don't know where to begin," Mann says. "Educating providers in communities that have not had this expertise can make a huge difference to people who might otherwise have to travel hundreds of miles for gender-affirming care."

NEW FACES

Wayne Brisbane, MD



Dr. Brisbane joins the UCLA Urology faculty as a health sciences assistant clinical professor after serving on the faculty at the University of Florida, where he began his academic career. Dr. Brisbane's clinical work focuses on prostate cancer diagnosis and treatment, including robotic prostatectomy; he sees patients primarily at UCLA Urology's Westwood location. His academic interests are in novel image-guided diagnosis and treatment for men with prostate cancer that leverages advances in bioengineering. Dr. Brisbane's work in micro-ultrasound imaging is funded by the Prostate Cancer Foundation and the Phase One Foundation. After earning his undergraduate degree from Seattle Pacific University and his MD from Loma Linda School of Medicine, Dr. Brisbane completed his urology residency training at the University of Washington and his fellowship in urologic oncology at UCLA.

M. Lynn Stothers, MD, MHSc



Dr. Stothers comes to UCLA Urology as a professor-in-residence after a distinguished academic career as a faculty member at the University of British Columbia. She has been an innovator in bladder dysfunction and integrative medicine, including work in functional MRI and near-infrared spectroscopy to investigate lower urinary tract dysfunction. In 2020, Dr. Stothers won the American Urological Association's prestigious Politano Award for her career-long excellence in clinical care and research in urinary incontinence and global health. Dr. Stothers' academic work will include close collaboration with UCLA's integrative medicine faculty, continuing her interests in pursuing novel strategies for both diagnosis and treatment of patients with urinary incontinence and bladder dysfunction. Dr. Stothers sees patients primarily in UCLA Urology's Santa Monica location focusing on urinary incontinence and

bladder dysfunction. She earned her MD and MHSc in health care and epidemiology from the University of British Columbia. Following her urology residency training at the University of British Columbia, Dr. Stothers completed her fellowship in female pelvic medicine and reconstructive surgery at UCLA. She holds a certificate of scholarship in educational leadership and is completing a fellowship in integrative medicine at the University of Arizona.

ALLIMNI PROFILE

Andrew T. Lenis, MD, MS



r. Andrew T. Lenis has landed the role he long aspired to as a surgeon-scientist on the Columbia University Irving Medical Center faculty, and he credits his UCLA Urology training with setting him on his career trajectory.

As an assistant professor of urology at Columbia, Dr. Lenis spends half his time

in clinical practice seeing patients with urologic cancers, and the other half as a translational bladder cancer researcher. Dr. Lenis works in the laboratory of Dr. Michael Shen, who pioneered the use of bladder tumor organoids to study the disease by creating three-dimensional cultures from patient tumor samples, improving the ability to investigate bladder tumor biology and responses to potential new treatments.

Dr. Lenis focuses on the molecular mechanisms and systemic immune implications of lymphovascular invasion and lymph node metastasis, a common occurrence in patients with invasive bladder cancer. His team uses next-generation sequencing, single-cell RNA sequencing, and organoids from patients Dr. Lenis sees in the clinic and operates on in the hospital. "Bladder cancer is very common, which provides a huge opportunity to help patients," Dr. Lenis says. "And it's interesting to study because there is such a wide spectrum of disease, each form bringing its own set of challenges. The field has progressed quickly over the last several years, which makes it an especially exciting time."

Dr. Lenis first became interested in studying bladder cancer as a UCLA Urology resident. He entered the program with laboratory experience studying pelvic disorders, but quickly gravitated toward oncology and began conducting clinical studies as a junior resident under the mentorship of Dr. Karim Chamie, a UCLA Urology associate professor who studies bladder cancer. When Dr. Lenis entered the fourth year of residency, which at UCLA is dedicated to research, he began to conduct laboratory studies of bladder cancer under Dr. Chamie's mentorship.

"Dr. Chamie and the department gave me the support and resources to pursue self-driven translational bladder cancer research, which started me on a path that I knew I wanted to continue," Dr. Lenis recalls. "I don't think I would been able to have that experience in many other places. And as I progress in my clinical practice, I really appreciate the clinical training I received at UCLA, where we had such a breadth of experiences — from the tertiary care referral center patients to the county and VA populations.

"Training under UCLA's outstanding physician investigators inspired me to want to synergize my clinical practice and research career, with the ultimate goal of taking patient samples from the clinic and the OR, studying them, and then one day taking something from the lab back into the clinic. It's a unique opportunity that I'm grateful to now have."

HEALTHY AT EVERY AGE

Undescended Testis

Indescended testis, also known by the medical term cryptorchidism, refers to a condition in which one or both of a boy's testicles fail to position themselves in the scrotum. During fetal development, the testicles start higher in the body, alongside the kidneys, then gradually move down a passageway called the inguinal canal before settling in the scrotum. In approximately 1-3% of male infants, one or both testes stop their descent at some point before reaching their destination. Undescended testis is more common in boys born prematurely.

Some boys born with undescended testis will experience a spontaneous descent within the first six months of life, meaning that the testis drops into the scrotum without any intervention, typically as a result of the testosterone surge that occurs during that time. If one or both testes remain undescended after six months – prematurely born babies should be given a few weeks beyond six months – it is highly unlikely that they will descend. At that point, the child should be referred to a pediatric urologist to help bring the testis down into the scrotum.

In almost all cases, undescended testis is treated surgically between the ages of 6 and 18 months. Early treatment is important because the scrotum provides a cooler environment for the testes, making it more hospitable for sperm production. Delaying treatment until later in childhood can increase future infertility risk. In addition, undescended testes are associated with an increased risk of testicular cancer. While bringing the testicle into the scrotum doesn't lower that risk, it significantly raises the likelihood that the cancer can be detected on an exam when it is still at an early, curable stage.

While most cases of undescended testis are present at birth, boys with normally descended testicles can experience either retractile testis or ascending testis later in childhood. When a child has retractile testis, the muscles around the testicle and spermatic cord pull the testicle up between the scrotum and the groin. In boys with an ascending testis, the testicle returns to the groin and can't easily be guided down into the scrotum, often requiring surgery.

When the testis can be felt in the inguinal canal, the treatment typically involves an open orchiopexy, in which small incisions by the inguinal canal and the scrotum are made to move the testicle. When it can't be felt, a small camera is inserted into the abdomen to perform a diagnostic laparoscopy in order to locate the testicle, and, if the testis is present, to move the testicle. Either surgery is extremely safe. The pediatric urologists at the Clark Morrison Children's Urological Center at UCLA treat patients with undescended testis; it is among the most common conditions they see.

For more information, visit www.uclaurology.com. To make an appointment, call (310) 794-7700.



Letter from the Chair



long with patient care and research, the educational mission represents a pillar of all major academic urology programs. Typically, this is defined as teaching and mentoring residents and fellows. At UCLA Urology, we take great pride in our track record of preparing the next generation of clinicians and scientists, many of whom go on to become leaders in the field and teachers in their own right, whether at UCLA or other institutions.

But our educational mission covers more than our core training programs. We also view it as our responsibility to spread knowledge and expertise outside of our department. As this issue's cover story illustrates, those efforts find wide-ranging audiences — including renowned surgeons and researchers, staff and faculty across the UCLA Health enterprise, community-based urology practitioners, and patients. We educate at professional meetings, trainings, and public forums, to name a few. Many members of our faculty venture overseas, presenting and sharing their advanced research and technical knowledge where the needs are greatest.

The benefits generated by these educational activities are both multipronged and bidirectional. For the individuals who attend UCLA Urology-led meetings, trainings, and informal exchanges, the experience not only brings content-specific knowledge; it also reinforces the value of lifelong learning. As faculty, we have much to gain as well — being challenged to synthesize our scholarship and summarize our expertise improves our own pedagogy, and fielding questions from peers and trainees alike compels us to think about our work from different perspectives, in many cases pointing us in new, previously unconsidered directions.

Above all, these educational endeavors serve our ultimate goal of improving patient outcomes, whether at UCLA, across the country, or around the world. By refining our own scholarship and disseminating that knowledge, we're helping to advance care. Raising awareness of urological issues among the general public results in better-informed patients, which tends to result in better outcomes. It all relates to our fourth pillar: Beyond providing state-of-the-art patient care, cutting-edge research that advances urologic health, and preparation of the next generation of leaders in health and medicine, we are committed to engaging with the world outside UCLA. That means fostering a culture of justice, equity, diversity, and inclusion; cultivating community partnerships; and doing our part to heal humankind, one patient at a time.

We view it as our responsibility to spread knowledge and expertise outside of our department.

* Mark S. Litwin, MD, MPH

Professor and Chair, UCLA Urology

Kudos

A. Lenore Ackerman, MD, PhD, UCLA



Urology assistant professor and director of research for the Division of Female Pelvic Medicine & Reconstructive Surgery, received the Society of

Urodynamics Female Pelvic Medicine and Urogenital Reconstruction 2023 Zimskind-McGuire Award. The award recognizes individuals who are within 10 years of completing their residency or fellowship and have made significant contributions to the field, primarily through basic and clinical research, as well as showing great potential for continuing and progressive scholarship.

Denise Asafu-Adjei, MD, former UCLA Urologic Sexual Dysfunction and Infertility fellow, received the 2023 Gallagher Health Policy Scholar award from the American Urological Association (AUA). The Gallagher Health Policy Scholar Program is a highly competitive, year-long intensive training program designed to prepare the next generation of urologists for leadership positions in health policy. The program was created in 2007 in honor of former AUA executive director G. James Gallagher.

Jonathan Bergman, MD, MPH, associate



professor of clinical urology and family medicine, was appointed inaugural holder of the newly established Mark S. Litwin, MD, Endowed Chair in Mentorship.

In this role, Dr. Bergman will continue to serve as teacher and mentor for medical students, residents, fellows, and junior faculty members. Dr. Bergman is highly regarded for his ebullient approach to pedagogy, insightful counsel, and ever-present support. He is also deeply committed to allyship, sponsorship, and the pursuit of justice, equity, diversity, and inclusion.

Richard J. Boxer, MD, UCLA Urology clinical professor, was appointed by President Biden to the National Cancer Advisory Board, which plays an important role in helping guide the director of the National Cancer Institute to set the course for the national cancer research program. Dr. Boxer has been a health policy adviser to the White House and has represented the United States at the World Health Organization. Recently, he was on the board of directors of the American Society of Clinical Oncology's Conquer Cancer foundation. With Michael A. Friedman, MD, Dr. Boxer had a manuscript, Point-Counterpoint: Screening vs diagnostic testing: Focus on the patient, not dogma," published in Urology Practice.

Chantal Efe Ghanney Simons, MD,

UCLA Urology chief resident, organized the fourth annual Road to Residency conference, a one-day conference for medical students nationally to participate in workshops, resident and faculty panels, and mock interviews, which supported nearly 200 medical students.

Andrew Goldstein, PhD, associate professor of urology and molecular, cell and developmental biology, received a Prostate Cancer Research Program Idea Development Award - Established Investigator grant from the Department of Defense's Congressionally Directed Medical Research Programs for "Role of Oxidative Mitochondrial Metabolism in Resistance to Androgen Receptor Inhibition."

Tommy Jiang, David Geffen School of Medicine at UCLA student, received a \$4,500 Sexual Medicine Society of North America Foundation Scholars in Sexuality Research grant for his project, "Prostate Bed Morphometry and Associated Radiation Toxicity in Post-Prostatectomy Patients Undergoing SBRT." He is co-mentored by Drs. Sriram Eleswarapu, Jesse N. Mills, Robert Reiter, and Amar Kishan.

Jesse N. Mills, MD, UCLA Urology clinical professor and director of the Men's Clinic at UCLA, received \$40,000 from ENDO International in support of the UCLA Urologic Sexual Dysfunction and Infertility Fellowship, which provides a post-residency training program in the clinical and surgical aspects of both disciplines.

Grace Sollender, MD, UCLA Urology resident, received a \$5,000 Sexual Medicine Society of North America Foundation Scholars in Sexuality Research grant for her project, "The Dilemma of the Adolescent Varicocele: A Qualitative Exploration of the Patient and Family Perspective." Dr. Sollender is co-mentored by Drs. Sriram Eleswarapu, Jennifer Singer, and Christopher Saigal.

Renea Sturm, MD, UCLA Urology assistant professor, along with her colleagues — Justine R. Yamashiro, J. Christopher Austin, Luis H. Braga, Kai-Wen Chuang, Carol A. Davis-Dao, Sarah Hecht, Sarah A. Holzman, Antoine E. Khoury, Eric A. Kurzrock, Steven E. Lerman, Melissa McGrath, Paul A. Merguerian, Amanda F. Saltzman, Anthony J. Schaeffer, Casey Seideman, Jennifer S. Singer, Peter Wang, Elias J. Wehbi, and Hsi-Yang Wu - had a manuscript, "Identifying variability in surgical practices and instrumentation for hypospadias repair across the Western Pediatric Urology Consortium (WPUC) network," published in the Journal of Pediatric Urology. The manuscript resulted from a multisite collaborative project with the goal of developing a surgical atlas of hypospadias repair techniques.

Bruce H. Lee



hen Bruce Lee's 19-year-old son Andrew was diagnosed in 2015 with stage 4 kidney cancer caused by a rare disease known as hereditary leiomyomatosis and renal cell cancer (HLRCC), Lee asked his son about any goals he had for his remaining time. A fan of the "Fast & Furious" movie franchise, Andrew joked about wanting to land

his dream car, a Nissan GT-R. Three weeks later, Bruce Lee made that dream come true.

Andrew was serious about another goal — raising awareness of HLRCC and other rare kidney cancers, and supporting research efforts to find a cure. And Bruce Lee devoted the rest of his life to fulfilling that dream as well.

They started Driven to Cure, a nonprofit organization that has become recognized as a key source of information for people with HLRCC as it promotes advocacy and funding for research on rare genetic forms of kidney cancer. In the four years Andrew lived with the disease, he worked with his brother to build a large following on

social media and took his beloved vehicle to more than two dozen car shows around the country — accompanied by his devoted father — to spread the word.

After Andrew passed away in 2019, Bruce Lee continued to tirelessly promote Driven to Cure's dual mission of supporting research and raising public awareness, right up until his own recent passing. "Bruce felt so passionate about this — in many ways it became his life's work," says Sarah Lee of her late husband. "And he had such a knack for it. Bruce was a people person who could really connect on a personal level with the patients and constituents Driven to Cure supports."

In his own effort to support the search for an HLRCC cure, Andrew Lee enrolled in a clinical trial at Yale, where he met Dr. Brian Shuch, now the Henry Alvin and Carrie L. Meinhardt Chair for Kidney Cancer Research and director of the UCLA Institute of Urologic Oncology Kidney Cancer Program. It was the start of a close and ongoing relationship between Dr. Shuch and the Lee family. Driven to Cure continues to support the research led by Dr. Shuch, both financially and through its declaration of the UCLA Kidney Cancer Program as a West Coast center of excellence for its diagnosis, treatment, and research into rare genetic kidney cancers such as HLRCC.

Driven to Cure has now raised more than \$1.2 million, and will continue to carry the torch started by Andrew Lee and picked up by his father. "It will look a little different because Bruce was so incredible at it," Sarah Lee says. "But the mission will remain the same."

IN MEMORIAM

Dr. Joy Paul, 1940-2022

Joy Paul, MD, a longtime UCLA Urology attending physician at Harbor-UCLA Medical Center, passed away last summer. Born in Kerala, India, in 1940, Dr. Paul had initially planned to become a cardiac surgeon, but during his surgical training in India, he was encouraged by a senior resident who had completed a UCLA Urology fellowship to follow the same path. He went to UCLA in 1972 for training in clinical transplantation, where his mentors included UCLA Urology's first two chiefs, Dr. Willard E. Goodwin and Dr. Joseph J. Kaufman. Following his training, Dr. Paul joined the Harbor-UCLA staff, as well as establishing a private practice in the South Bay with two other urologists.

Dr. Paul was married for 53 years to his wife Elizabeth, a physical medicine and rehabilitation doctor; the couple met on Elizabeth's first day as a student at Christian Medical College in Punjab, India. They had two children — George, an anesthesiologist, and Kavita, an attorney whose husband, Dr. Timothy Lesser, joined Dr. Paul's practice as a urologist. "From the beginning to the end, UCLA has been so good to us," Dr. Elizabeth Paul said.

Dr. Bimal Masih, 1935-2022

Bimal Masih, MD, who completed training as a UCLA Urology resident in 1971 and went on to serve for many years as chief of urology at Kaiser Permanente in Panorama City, California, passed away late last year. Dr. Masih graduated from Madras Medical College in India in 1959, then completed his surgical and urology training in India before moving to the U.S. Following his residency, he became the first UCLA Urology graduate to join the Southern California Permanente Medical Group.

Known as an outstanding adult and pediatric surgeon, Dr. Masih mentored many UCLA Urology residents in the operating room as a clinical attending urologist at Olive View-UCLA Medical Center. In addition, he offered an introductory clinical urology course for medical students. After his retirement in 1997, he continued to work for the next 24 years performing shockwave lithotripsy for the department twice a month. He and his wife, Sulabha, regularly attended the department's holiday party. Dr. Masih is remembered for his friendship, kindness, humility, and compassion — someone who loved being in the hospital, caring for patients, and stopping in to say hello to his friends after the operating room work was completed.





UCLA Urology 405 Hilgard Avenue Box 951738 Los Angeles, CA 90095-1738 NONPROFIT ORGANIZATION U.S. POSTAGE

> PAID UCLA



UCLA Health hospitals in Westwood and Santa Monica placed # 5 in the nation in the 2022-23 U.S. News and World Report rankings.



The Men's Clinic at UCLA

DID YOU KNOW?

Vasectomy rates among men have increased nationwide since the recent Supreme Court decision on women's health. Urologists at the Men's Clinic at UCLA perform in-office vasectomy.

The Men's Clinic at UCLA is a comprehensive, multidisciplinary health and wellness center located in Santa Monica, now with locations in Burbank and Santa Clarita. For more information or to make an appointment, call (310) 794-7700.



Give Now. Here's How. Contributions to UCLA Urology support our research programs and help our faculty make the cutting-edge discoveries that can save lives. You can make a gift to UCLA Urology by logging on to http://giving.ucla.edu/urology. Please call (310) 206-4565 if you have any questions about making a gift to UCLA Urology.

UPDATE

Spring 2023 | VOL. 34 | NO. 2

DEPARTMENT CHAIR

Mark S. Litwin, MD, MPH

CHIEF ADMINISTRATIVE OFFICER

Laura A. Baybridge

EDITOR

Dan Gordon

EDITORIAL ADVISORS

Sarah E. Connor, MPH Gretchen McGarry

DESIGN

Wildhirt Fowlkes Graphics, Inc.



VISIT UCLA UROLOGY'S WEBSITE:

www.urology.ucla.edu

Copyright © 2023 by UCLA Urology All rights reserved.

Urology Appointment Line: (310) 794-7700 UCLA Urology Website: www.urology.ucla.edu



If you received multiple copies of this newsletter, please feel free to share one with a friend or colleague.